Now accepting Telehealth appointments. Schedule a virtual visit.

Practical impact of COVID-19 on CHR patients, individualizing DOR treatment & more

Practical impact of COVID-19 on CHR patients, individualizing DOR treatment & more

Dr. Gleicher's live webinar on DHEA was attended by over 4,000 viewers.

May 2020 CHR VOICE Digest

During April, the coronavirus and COVID-19, in all spheres of life, continued to dominate the nation’s existence. That, of course, also applies here at CHR. We are, however, very pleased to report that so-far only one of our staff members has contracted the virus. She has been home for over a month and is recovering well. CHR has continued to function “normally,” if anything can still be considered to function “normally” these days. In practical terms, CHR, in contrast to most other IVF centers in New York City and the country, never shut down. We have curtailed non-urgent clinical activities but continued to offer all treatments our patients and CHR concurred were urgent, relying on the telemedicine capabilities we've developed over the years for our international and US long-distance patients.

The COVID-19 pandemic, unsurprisingly, also still dominates this issue of the VOICE. But we, in addition, also are discussing some clinical issues that attracted enormous attention during a worldwide virtual professional infertility conference in April. The conference was expected to attract notmore than 1,000 virtual attendees; yet, it ended up with over 14,000 fertility specialists joining online. A lecture on the clinical utilization of dehydroepiandrosterone (DHEA) by CHR’s Medical Director and Chief Scientist, Norbert Gleicher, MD, attracted the largest number of immediate downloads at the conference (over 4,000, and a few thousand additional ones over the following days). Because of this unexpected and overwhelming interest in the subject of low functional ovarian reserve (LFOR),we decided to initiate with this issue of the VOICE a detailed series of articles on how to individualize treatments in women with LFOR. Here we present the first installment.

In this issue of the CHR VOICE, we cover:

Norbert Gleicher, MD

Norbert Gleicher, MD, FACOG, FACS

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.

Follow on LinkedIn    

Watch his videos on YouTube    

 


We have helped women bring over
17,800 babies into the world.

DISCOVER YOUR TREATMENT OPTIONS

 

You Might Also Enjoy...

March VOICE

We welcome all of our readers to the March issue of The CHR VOICE, which, as usual, in the new and expanded format offers a broad potpourri of articles for patients and laypeople as well as professional physicians and scientists working in reproductive med

The Voice February 2023

We are very pleased to offer the February 2023 issue of THE CHR VOICE and want to take the opportunity of this introduction to direct the attention of our readers...

The Voice January 2023

With this January issue, we are very pleased for the year 2023 to welcome back to TheVOICE; the monthly newsletter of the CHR,-you, our reader.

The Voice December 2022

With the year 2002 is almost behind us, it is easy to conclude that it on many different levels was an unusually tumultuous year.

The Voice November 2022

The CHR is delighted to offer the VOICE's November issue to our readers, as always attempting to present material for our very diverse readership.